Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001062094 | SCV001226870 | uncertain significance | Hereditary spastic paraplegia 11 | 2022-08-09 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 1184 of the SPG11 protein (p.Ser1184Ile). This variant is present in population databases (rs766403944, gnomAD 0.05%). This missense change has been observed in individual(s) with clinical features of SPG11-related conditions (Invitae). ClinVar contains an entry for this variant (Variation ID: 856597). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003160501 | SCV003870997 | uncertain significance | Inborn genetic diseases | 2023-02-01 | criteria provided, single submitter | clinical testing | The c.3551G>T (p.S1184I) alteration is located in exon 21 (coding exon 21) of the SPG11 gene. This alteration results from a G to T substitution at nucleotide position 3551, causing the serine (S) at amino acid position 1184 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV003223695 | SCV003919396 | uncertain significance | not provided | 2023-04-12 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |
Athena Diagnostics | RCV003223695 | SCV004229163 | uncertain significance | not provided | 2022-11-17 | criteria provided, single submitter | clinical testing | Available data are insufficient to determine the clinical significance of the variant at this time. The frequency of this variant in the general population is uninformative in assessment of its pathogenicity (http://gnomad.broadinstitute.org). Computational tools disagree on the variant's effect on normal protein function. |
Revvity Omics, |
RCV003223695 | SCV004237658 | uncertain significance | not provided | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV003223695 | SCV005193765 | uncertain significance | not provided | criteria provided, single submitter | not provided |